Home Article Formulation and Evaluation of Eudragit RS100 Nanoparticles

Research Article

Formulation and Evaluation of Eudragit RS100 Nanoparticles


Patel, C. J., Patel, D. V.

Author's Affiliation


The Glibenclamide is a drug of choice for the physician for Non-Insulin Dependent Diabetes (NIDD). The drug in oral conventional dosage form has the dosage regime of three times a day. The repeated administration in a day may cause noncompliance by the patients. Thus, it is emphasized to prolong/sustain release delivery of the drug to avoid repeated administration. The objective of the present study was to develop Glibenclamide loaded nanoparticles using Eudragit RS100 as release control polymer. Different ratio of Drug: Eudragit RS100 was tried. The prepared nanoparticles were evaluated for particle size, zeta potential, % yield, Association efficiency, CPR. In-vivo anti-hyperglycemic activity of the FN8 batch was studied. The formulation containing 1:4 ratio of Drug:Eudragit RS100 was selected as best formulation.


Glibenclamide, Eudragit RS100, Nanoparticle, Factorial Design, Optimization

Cite This Article

Patel, C. J., & Patel, D. V. (2014). Formulation and Evaluation of Eudragit RS100 Nanoparticles Containing Glibenclamide, International Journal for Pharmaceutical Research Scholars (IJPRS), 3(4), 165-173.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Articles